Dr. Jeffrey Stavenhagen brings 20 years of scientific leadership experience in both the US and Europe using emerging technology platforms for the development of novel biologics. Most recently as a Senior Director at Lundbeck (Denmark) he lead their global biologics program for the treatment of CNS diseases. Prior to that, he served as Director, Molecular Immunology at Amplimmune. Dr. Stavenhagen held roles of increasing responsibility at MacroGenics. Dr. Stavenhagen started his career as an assistant professor at the University of Dayton in the Department of Biology. He received his Ph.D. in molecular biology from Columbia University and conducted Post-Doctoral research at the Fred Hutchinson Cancer Research Center in Seattle, Washington
Molecular Immunology